Moxonidine, a Mixed α2-Adrenergic and Imidazoline Receptor Agonist, Identifies a Novel Adrenergic Target for Spinal Analgesia

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Moxonidine is a mixed α2-adrenergic and imidazoline receptor agonist with an improved side effect profile compared to clonidine. Intrathecal (i.t.) moxonidine has been found to possess analgesic activity that, in contrast to the majority of α2-adrenoceptor (α 2AR) agonists, does not require activation of the α 2AAR subtype, which mediates many of the side effects associated with α2AR use. In addition, moxonidine (i.t.) interacts in a synergistic manner with opioid agonists and this synergy is retained in neuropathic pain states. Moxonidine may therefore be clinically useful in the treatment of chronic neuropathic pain, either alone or as a coadjuvant with opioids.

Original languageEnglish (US)
Pages (from-to)378-385
Number of pages8
JournalAnnals of the New York Academy of Sciences
Volume1009
DOIs
StatePublished - Jan 1 2003

Keywords

  • Intrathecal
  • Pain
  • Synergy
  • α adrenergic receptor

Fingerprint Dive into the research topics of 'Moxonidine, a Mixed α<sub>2</sub>-Adrenergic and Imidazoline Receptor Agonist, Identifies a Novel Adrenergic Target for Spinal Analgesia'. Together they form a unique fingerprint.

  • Cite this